Business Context and Reporting Period
This Form 8-K was filed by Hemispherx Biopharma, Inc. on September 9, 2013. The report addresses corporate governance amendments regarding the company's 2013 annual meeting of stockholders.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate bylaw amendments and does not contain financial performance data.
Material Changes
On September 9, 2013, the Board of Directors amended the company's Restated and Amended By-Laws. The amendment reduces the quorum requirement for the 2013 annual meeting of stockholders from a majority (50%) of outstanding voting shares to one-third (33.3%) of outstanding voting shares.
Outlook, Risks, and Management Commentary
- Reason for Change: Management expressed concern that the company would fail to obtain the standard 50% quorum, which would necessitate postponing the 2013 annual meeting.
- Shareholder Base: Approximately 40% of the company's shares are held by persons or organizations in Europe, historically creating difficulty in achieving a quorum.
- Scope: The reduced quorum applies solely to the 2013 annual meeting.
Key Facts for Investor Verification
- Verify the specific date and agenda of the 2013 annual meeting of stockholders.
- Confirm whether the reduced quorum threshold was successfully met at the meeting.
- Review the attached Exhibit 3.1 for the full text of the Amended and Restated Bylaws.
- Note that this filing contains no financial results or operational updates.